Last week's news of health/biotech
ActiTrexx Raises €3.5M in Series A Funding
ActiTrexx GmbH, a new biotech spin-off from the University Medical Center Mainz, Germany, closed its €3.5m Series A financing.
The round was led by LBBW Venture Capital GmbH with participation from MediVentures GmbH, High-Tech Gründerfonds (HTGF) and Investitions- und Strukturbank Rheinland-Pfalz (ISB).
The company intends to use the funds to further optimize and clinically test the novel cell therapy. The first clinical trials for the treatment of leukemia patients who have undergone stem cell transplantation and are at particularly high risk of a life-threatening transplant rejection, graft-versus-host disease (GvHD), is particularly high, are due to start as early as 2021. https://www.finsmes.com/2021/03/actitrexx-raises-e3-5m-in-series-a-funding.html
VisionHealth Raises €1.5M in Funding
VisionHealth GmbH, a Garching, Germany-based provider of digital therapy support in inhalation therapy for the treatment of chronic respiratory diseases, closed a €1.5m financing round.
Backers included Dr. Thomas Ecker, the Vantage Value GmbH, a Family Office in Eching (Germany). Erwin J. Schimmer of Vantage Value will take a seat on VisionHealth’s board of directors.
The company will use the funds to conduct a health economic trial and complete the approval process of the Kata app by the German Federal Institute for Drugs and Medical Devices, BfArM, as a Digital Health Application within the framework of the German Digital Health Care Act (DVG), which will enable permanent reimbursement by German health insurance companies, to enter the market in Germany and generate revenue, via licensing Kata® to pharmaceutical and medtech companies. https://www.finsmes.com/2021/02/visionhealth-raises-e1-5m-in-funding.html
Amsterdam-based Founda Health raises €12.3M to build infrastructure for global healthcare sector; here’s how
Founda Health is a technology company that builds infrastructure for the global healthcare sector. Today, this Amsterdam-based company has announced that it has raised $15M (nearly €12.3M) from a group of healthcare and fintech entrepreneurs.
According to the company, this investment would help the company with international expansion, along with financing further development of the platform and integrations with Electronic Health Record (EHR) systems. https://siliconcanals.com/news/startups/founda-health-raises-12-3m/
Cambridge-based Better Origin lands €2.5 million to democratise insect farming with automation and machine learning
Better Origin, a Cambridge-based biotech startup on a mission to democratise insect farming through automation and machine learning technology, has announced closing a funding round of around €2.5 millon.
The funding was led by Fly Ventures, a Berlin-based VC firm that invests in deep technology and AI-driven venture startups. Previous investors, Athens based Metavallon VC also participated in the round.
Founded in 2019, the company’s product – the X1 – is one of the world’s first insect mini-farms that converts local food waste into high-quality animal feed in the form of insect larvae. The upcycling of nutrients mimics nature’s processes and is a step closer to a more circular economy and a better future for our planet.
With the recent funding, the company could see their scalable solution applied to hundreds of farms across the UK and the world. https://www.eu-startups.com/2021/02/cambridge-based-better-origin-lands-e2-5-million-to-democratise-insect-farming-with-automation-and-machine-learning/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+eu-startups+%28EU-Startups%29
Axis Spine Technologies Raises £2.2M in Funding
Axis Spine Technologies, a UK-based MedTech startup, closed a £2.2m funding round.
The round was led by ACF Investors’ Delta Fund with follow-on investment from Mercia’s EIS funds. An angel syndicate led by Simon Cartmell, who has more than 40 years pharmaceutical, biotech and medtech experience, participated.
The funding will be used to support the launch of the new device in the USA, and also to progress developments of Oblique, Lateral cage implants, as well as a highly differentiated access system. https://www.finsmes.com/2021/02/axis-spine-technologies-raises-2-2m-in-funding.html
Cellarity Raises $123M in Series B Funding
Cellarity, a Cambridge, Mass.-based life sciences company developing a new method of drug discovery targeting the cell, raised $123m in Series B financing.
The round included contributions from funds and accounts managed by BlackRock, The Baupost Group, Banque Pictet on behalf of their clients and eight other investors alongside Flagship Pioneering.
Founded in 2017 within Flagship Labs, Cellarity is designing medicines against the cell as opposed to a single molecular target. The company has developed a combination of expertise across system and network biology, high-resolution data, and machine learning to unlock treatments in a large number of therapeutic areas.
The company is led by Fabrice Chouraqui, CEO of Cellarity and a CEO-Partner at Flagship Pioneering.
